A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

• Status: Completed
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Evaluate 18F-AV-45 positron emission tomography (PET) imaging for distinguishing healthy control subjects, from subjects with Alzheimer's disease (AD) or Mild cognitive impairment (MCI).

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Avid Radiopharmaceuticals

Criteria

Inclusion Criteria AD:

• Male or female >=50 years of age

• Meet National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS) criteria for probable AD with MMSE score of 10-24

Inclusion Criteria MCI:

• Male or female >=50 years of age

• Have a Clinical Dementia Rating (CDR) of 0.5

• MMSE >24

Normal subjects:

• Male or female >=50 years of age

• MMSE >=29

• Normal on psychometric test battery at screening

• Provide informed consent

Exclusion Criteria:

• Have a history or current diagnosis of other neurologic disease

• Have had or currently have a diagnosis of other neurodegenerative disease

• Have participated in experimental therapy targeted to amyloid plaque